Bloating and intestinal gas

Current Treatment Options in Gastroenterology

Volumn 8, Issue 4, 2005, Pages 311-318

  Jones, Michael P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ALPHA GALACTOSIDASE; ANTACID AGENT; ANTIBIOTIC AGENT; BETA GLUCOSIDASE; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; LACTASE; NEOMYCIN; NEOSTIGMINE; ONDANSETRON; PEPPERMINT OIL; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; SIMETHICONE; SPASMOLYTIC AGENT; TEGASEROD; TETRACYCLINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; AEROPHAGIA; BEHAVIOR THERAPY; BLOATING; CARBOHYDRATE INTAKE; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIET THERAPY; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG POTENTIATION; DYSPEPSIA; ERUCTATION; FECES COLOR; FLATULENCE; GAS TRANSPORT; HEART FAILURE; HEARTBURN; HUMAN; INDIGESTION; IRRITABLE COLON; KIDNEY FAILURE; LIFESTYLE; MENTAL DISEASE; META ANALYSIS; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PNEUMATOSIS INTESTINALIS; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TIC; UNCONSCIOUSNESS; VISUAL IMPAIRMENT; VOMITING;

EID: 24044550948     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-005-0024-x     Document Type: Review

References (57)

1. Levitt MD: Volume and composition of human intestinal gas determined by means of an intestinal washout technic. N Engl J Med 1971, 284:1394-1398.
2. Serra J, Azpiroz F, Malagelada JR: Intestinal gas dynamics and tolerance in humans. Gastroenterology 1998, 115:542-550.
3. Suarez F, Levitt MD: Intestinal gas. In Sleisenger & Fordtran's Gastrointestinal and Liver Disease:Pathophysiology/Diagnosis/Management. Feldman M, Friedman LS, Sleisenger MH, eds. 7th ed. Philadelphia: W.B. Saunders Co, 2002:155-163.
4. Serra J, Azpiroz F, Malagelada JR: Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001, 48:14-19.
5. Maxton DG, Martin DF, Whorwell PJ, Godfrey M: Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms. Gut 1991, 32:662-664.
6. Koide A, Yamaguchi T, Odaka T, et al.: Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95:1735-1741.
7. Chami TN, Schuster MM, Bohlman ME, et al.: A simple radiologic method to estimate the quantity of bowel gas. Am J Gastroenterol 1991, 86:599-602.
8. Haderstorfer B, Psycholgin D, Whitehead WE, Schuster MM: Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome. Am J Gastroenterol 1989, 84:375-378.
9. King TS, Elia M, Hunter JO: Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998, 352:1187-1189.
10. Lasser RB, Bond JH, Levitt MD: The role of intestinal gas in functional abdominal pain. N Engl J Med 1975, 293:524-526.
11. Serra J, Azpiroz F, Malagelada JR: Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation. Am J Physiol Gastrointest Liver Physiol 2001, 281:G138-G143.
12. Gauderer MW, Halpin TC, Jr., Izant RJ, Jr: Pathologic childhood aerophagia: a recognizable clinical entity. J Pediatr Surg 1981, 16:301-305.
13. Rosenbach Y, Zahavi I, Nitzan M, Dinari G: Pathologic childhood aerophagy: an under-diagnosed entity. Eur J Pediatr 1988, 147:422-423.
14. Zella SJ, Geenens DL, Horst JN: Repetitive eructation as a manifestation of obsessive-compulsive disorder. Psychosomatics 1998, 39:299-301.
15. D'Mello D: Aerophagia and depression: case report. J Clin Psychiatry 1983, 44:387-388.
16. Rao SS: Belching, bloating, and flatulence. How to help patients who have troublesome abdominal gas. Postgrad Med 1997, 101:263-269, 275-278.
17. Barrett RP, McGonigle JJ, Ackles PK, Burkhart JE: Behavioral treatment of chronic aerophagia. Am J Ment Defic 1987, 91:620-625.
18. Calloway SP, Fonagy P, Pounder RE, Morgan MJ: Behavioural techniques in the management of aerophagia in patients with hiatus hernia. J Psychosom Res 1983, 27:499-502.
19. Levitt MD, Furne J, Olsson S: The relation of passage of gas an abdominal bloating to colonic gas production. Ann Intern Med 1996, 124:422-424.
20. Suarez FL, Springfield J, Levitt MD: Identification of gases responsible for the odour of human flatus and evaluation of a device purported to reduce this odour. Gut 1998, 43:100-104.
21. Di Stefano M, Miceli E, Armellini E, et al.: Probiotics and functional abdominal bloating. J Clin Gastroenterol 2004, 38(Suppl 6):S102-S103.
22. Di Stefano M, Strocchi A, Malservisi S, et al.: Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 2000, 14:1001-1008.
23. Lewis MJ, Reilly B, Houghton LA, Whorwell PJ: Ambulatory abdominal inductance plethysmography: towards objective assessment of abdominal distension in irritable bowel syndrome. Gut 2001, 48:216-220.
24. Azpiroz F, Enck P, Whitehead WE: Anorectal functional testing: review of collective experience. Am J Gastroenterol 2002, 97:232-240.
25. Hernando-Harder AC, Serra J, Azpiroz F, Malagelada JR: Sites of symptomatic gas retention during intestinal lipid perfusion in healthy subjects. Gut 2004, 53:661-665.
26. Lin HC, Chen JH: Slowing of intestinal transit by fat depends on an ondansetron-sensitive, efferent serotonergic pathway. Neurogastroenterol Motil 2003, 15:317-322.
27. Evans PR, Kellow JE: Physiological modulation of jejunal sensitivity in health and in irritable bowel syndrome. Am J Gastroenterol 1998, 93:2191-2196.
28. Kellow JE, Eckersley CM, Jones MP: Enhanced perception of physiological intestinal motility in the irritable bowel syndrome. Gastroenterology 1991, 101:1621-1627.
29. Galati JS, McKee DP, Quigley EM: Response to intraluminal gas in irritable bowel syndrome. Motility versus perception. Dig Dis Sci 1995, 40:1381-1387.
30. Dainese R, Serra J, Azpiroz F, Malagelada JR: Influence of body posture on intestinal transit of gas. Gut 2003, 52:971-974.
31. Dainese R, Serra J, Azpiroz F, Malagelada JR: Effects of physical activity on intestinal gas transit and evacuation in healthy subjects. Am J Med 2004, 116:536-539.
32. Gonlachanvit S, Coleski R, Owyang C, Hasler W: Inhibitory actions of a high fibre diet on intestinal gas transit in healthy volunteers. Gut 2004, 53:1577-1582.
33. Suarez FL, Savaiano DA, Levitt MD: A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995, 333:1-4.
34. Delgado-Aros S, Locke GR, 3rd, Camilleri M, et al.: Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol 2004, 99:1801-1806.
35. Talley NJ, Quan C, Jones MP, Horowitz M: Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. Neurogastroenterol Motil 2004, 16:413-419.
36. Caldarella MP, Serra J, Azpiroz F, Malagelada JR: Prokinetic effects in patients with intestinal gas retention. Gastroenterology 2002, 122:1748-1755.
37. Johanson JF, Wald A, Tougas G, et al.: Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004, 2:796-805.
38. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al.: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001, 15:1655-1666.
39. Poynard T, Regimbeau C, Benhamou Y: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001, 15:355-361.
40. Ganiats TG, Norcross WA, Halverson AL, et al.: Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. J Fam Pract 1994, 39:441-445.
41. Rosado JL, Solomons NW, Lisker R, Bourges H: Enzyme replacement therapy for primary adult lactase deficiency. Effective reduction of lactose malabsorption and milk intolerance by direct addition of beta-galactosidase to milk at mealtime. Gastroenterology 1984, 87:1072-1082.
42. Lisker R, Solomons NW, Perez Briceno R, Ramirez Mata M: Lactase and placebo in the management of the irritable bowel syndrome: a double-blind, cross-over study. Am J Gastroenterol 1989, 84:756-762.
43. Brecevic L, Bosan-Kilibarda I, Strajnar F: Mechanism of antifoaming action of simethicone. J Appl Toxicol 1994, 14:207-211.
44. Holtmann G, Gschossmann J, Karaus M, et al.: Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia. Aliment Pharmacol Ther 1999, 13:1459-1465.
45. Holtmann G, Gschossmann J, Mayr P, Talley NJ: A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Aliment Pharmacol Ther 2002, 16:1641-1648.
46. Suarez FL, Furne J, Springfield J, Levitt MD: Failure of activated charcoal to reduce the release of gases produced by the colonic flora. Am J Gastroenterol 1999, 94:208-212.
47. Hills JM, Aaronson PI: The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology 1991, 101:55-65.
48. Spanier JA, Howden CW, Jones MP: A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003, 163:265-274.
49. Liu JH, Chen GH, Yeh HZ, et al.: Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997, 32:765-768.
50. Sen S, Mullan MM, Parker TJ, et al.: Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002, 47:2615-2620.
51. Nobaek S, Johansson ML, Molin G, et al.: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95:1231-1238.
52. Kim HJ, Camilleri M, McKinzie S, et al.: A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17:895-904.
53. Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503-3506.
54. Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412-419.
55. Di Stefano M, Malservisi S, Veneto G, et al.: Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000, 14:551-556.
56. Lea R, Houghton LA, Calvert EL, et al.: Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17:635-642.
57. Houghton LA, Calvert EL, Jackson NA, et al.: Visceral sensation and emotion: a study using hypnosis. Gut 2002, 51:701-704.